Region: Australia

Australian government will push for inventive step reform and abolition of second-tier patents

Over the weekend, Australia’s government responded to a lengthy list of IP system reforms proposed last year by the country’s Productivity Commission, a top policy advisory body. Among other changes, the country’s second-tier “innovation patent”…

30 August 2017

IP value in the lands down under

Australia and New Zealand have the expertise, the investment and the right economic conditions to become high-tech innovation dynamos. What they need now is an IP strategy

01 June 2017

CSIRO sees “virtuous cycle” in reinvesting patent monetisation cash directly into commercialisation push

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) – Australia’s national R&D agency – announced this week the creation of a new technology commercialisation fund that will be capitalised using patent assertion and licensing…

09 December 2016

IP lawyer: Amped-up protection on the cards for recombinant DNA products

Australian patent authorities continue to wrestle with the treatment of gene-related inventions. A new ruling may extend the life of patents covering medicines made with recombinant DNA technology

01 December 2016

Co-opetition, commercialisation and much more discussed at the first-ever IPBC Down Under

The IPBC brand came to the Southern Hemisphere for the first time yesterday. Hosted by IAM at the Sofitel in Melbourne, IPBC Australasia attracted around 200 delegates and speakers from Australia, New Zealand and the rest of the world. Reflecting…

11 November 2016

Patent strategies for the ASEAN region

Featured in IAM Yearbook 2017

Are you or your clients developing an international patenting strategy? If so, you should consider the world’s seventh-largest economy, particularly as it is projected to become the fourth largest. This regional economy is the Association of…

12 October 2016

In a field of flops, this IP stock gained over 150% in value last year

Considering the evidence, last year was a particularly disappointing one overall for publicly traded IP-centric companies and their investors. The PIPX – an index of patent monetisation company stocks compiled by former Freescale Semiconductor…

29 January 2016

Vringo's $21.5 million global settlement with ZTE reflects the IP market's new realities

US PIPCO Vringo announced late yesterday that its Vringo Infrastructure subsidiary had reached a litigation settlement and licence agreement with Chinese telecoms major ZTE, bringing to an end a sprawling, multi-jurisdictional and at times…

08 December 2015

A possible silver lining for Australia's biotech innovators after bombshell Myriad decision

IP owners everywhere are well aware that a ruling on patent eligibility from a country’s highest court can turn a market on its head overnight. As IAM has detailed in the past, the extent to which an IP office offers well-defined guidance on those…

20 October 2015

High Court: Myriad's BRCA genes not patentable subject matter

Just over one year after the Full Federal Court of Australia unanimously upheld an earlier Federal Court decision that naturally occurring nucleic acid molecules are patentable in Australia, the High Court has handed down a unanimous judgment overturning that decision. This highly anticipated decision sets Australian law at odds with that of many other jurisdictions where isolated nucleic acid molecules remain patentable.

14 October 2015

Unlock unlimited access to all IAM content